BR112015029090A2 - compostos de 3,4-di-hidroisoquinolin-2(1h)-ila - Google Patents

compostos de 3,4-di-hidroisoquinolin-2(1h)-ila

Info

Publication number
BR112015029090A2
BR112015029090A2 BR112015029090A BR112015029090A BR112015029090A2 BR 112015029090 A2 BR112015029090 A2 BR 112015029090A2 BR 112015029090 A BR112015029090 A BR 112015029090A BR 112015029090 A BR112015029090 A BR 112015029090A BR 112015029090 A2 BR112015029090 A2 BR 112015029090A2
Authority
BR
Brazil
Prior art keywords
compounds
dihydroisoquinolin
formula
schizophrenia
parkinson
Prior art date
Application number
BR112015029090A
Other languages
English (en)
Other versions
BR112015029090B1 (pt
BR112015029090A8 (pt
Inventor
David Beadle Christopher
Daniel Wolfangel Craig
Andrew Coates David
Mehnert Schaus John
Herman Krushinski Joseph Jr
Hao Junliang
Robert Reinhard Matthew
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112015029090A2 publication Critical patent/BR112015029090A2/pt
Publication of BR112015029090A8 publication Critical patent/BR112015029090A8/pt
Publication of BR112015029090B1 publication Critical patent/BR112015029090B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "compostos de 3,4-di-hidroisoquinolin-2(1h)-ila". a presente invenção refere-se a alguns compostos de 3,4-di-hidroisoquinolin-2(1h)-ila, particularmente compostos de fórmula i, e composições farmacêuticas dos mesmos. a invenção adicionalmente proporciona métodos de uso de um composto de fórmula i para tratar transtorno cognitivo associado com doença de parkinson ou esquizofrenia. i
BR112015029090-6A 2013-05-30 2014-05-27 3,4-dihidroisoquinolin-2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina BR112015029090B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361828740P 2013-05-30 2013-05-30
US61/828,740 2013-05-30
US201361905329P 2013-11-18 2013-11-18
US61/905,329 2013-11-18
PCT/US2014/039494 WO2014193781A1 (en) 2013-05-30 2014-05-27 3,4-dihydroisoquinolin-2(1h)-yl compounds

Publications (3)

Publication Number Publication Date
BR112015029090A2 true BR112015029090A2 (pt) 2017-07-25
BR112015029090A8 BR112015029090A8 (pt) 2020-03-17
BR112015029090B1 BR112015029090B1 (pt) 2023-05-09

Family

ID=50983199

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029090-6A BR112015029090B1 (pt) 2013-05-30 2014-05-27 3,4-dihidroisoquinolin-2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina

Country Status (38)

Country Link
US (1) US8962654B2 (pt)
EP (1) EP3004061B8 (pt)
JP (2) JP6130590B2 (pt)
KR (1) KR101808933B1 (pt)
CN (1) CN105228985B (pt)
AP (1) AP2015008867A0 (pt)
AU (2) AU2014274435B2 (pt)
BR (1) BR112015029090B1 (pt)
CA (1) CA2912849C (pt)
CL (1) CL2015003444A1 (pt)
CR (1) CR20150622A (pt)
CY (1) CY1119361T1 (pt)
DK (1) DK3004061T3 (pt)
DO (1) DOP2015000289A (pt)
EA (1) EA029220B1 (pt)
ES (1) ES2647086T3 (pt)
GT (1) GT201500334A (pt)
HK (1) HK1216314A1 (pt)
HR (1) HRP20171696T1 (pt)
HU (1) HUE034607T2 (pt)
JO (1) JO3316B1 (pt)
LT (1) LT3004061T (pt)
ME (1) ME02838B (pt)
MX (1) MX2015016495A (pt)
MY (1) MY180751A (pt)
NZ (1) NZ713809A (pt)
PE (1) PE20152032A1 (pt)
PH (1) PH12015502658B1 (pt)
PL (1) PL3004061T3 (pt)
PT (1) PT3004061T (pt)
RS (1) RS56294B1 (pt)
SG (1) SG11201509310QA (pt)
SI (1) SI3004061T1 (pt)
TN (1) TN2015000514A1 (pt)
TW (2) TWI691488B (pt)
UA (1) UA118759C2 (pt)
WO (1) WO2014193781A1 (pt)
ZA (1) ZA201508213B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458119B2 (en) 2009-11-27 2022-10-04 Genzyme Corporation Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
WO2017178377A1 (en) 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
IL269379B (en) 2017-02-21 2022-06-01 Univ Emory cxcr4 receptor modulators and related uses
EP3418270A1 (en) 2017-06-19 2018-12-26 Universidad Complutense De Madrid Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
MA51199A (fr) 2017-12-01 2020-10-07 UCB Biopharma SRL Agents d'imagerie
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
JP2022514659A (ja) 2018-12-18 2022-02-14 イーライ リリー アンド カンパニー ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
EP3993794A1 (en) * 2019-07-01 2022-05-11 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MA56445A (fr) 2019-07-01 2022-05-11 UCB Biopharma SRL Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
EP4267555A1 (en) 2020-12-03 2023-11-01 UCB Biopharma SRL Octahydroisoquinolinyl derivatives
WO2022129356A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
MX2023007155A (es) 2020-12-18 2023-06-28 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como un modulador alosterico positivo de d1.
WO2022129267A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Amorphous solid dispersions
JP2023554033A (ja) * 2020-12-18 2023-12-26 ユーシービー バイオファルマ エスアールエル ジヒドロイソキノリニル誘導体
WO2022192231A1 (en) 2021-03-08 2022-09-15 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
EP4304577A1 (en) 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68910999T2 (de) 1988-02-19 1994-03-24 Smithkline Beecham Farma 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten.
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ZA991301B (en) 1998-02-18 1999-09-13 Neurosearch As Glutamate receptor modulators.
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
BRPI0808525A2 (pt) * 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
BR112014015081A2 (pt) 2011-12-21 2017-06-13 Actelion Pharmaceuticals Ltd derivados heterocíclicos e seu uso como moduladores do receptor d2 de prostaglandina
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
LT3004061T (lt) 2017-11-27
CN105228985B (zh) 2017-05-10
EA029220B1 (ru) 2018-02-28
ES2647086T3 (es) 2017-12-19
GT201500334A (es) 2018-11-23
CY1119361T1 (el) 2018-02-14
TWI691489B (zh) 2020-04-21
AU2016238934A1 (en) 2016-10-27
PH12015502658A1 (en) 2016-03-07
HUE034607T2 (en) 2018-02-28
EP3004061A1 (en) 2016-04-13
HK1216314A1 (zh) 2016-11-04
CL2015003444A1 (es) 2016-07-15
WO2014193781A1 (en) 2014-12-04
AU2016238934B2 (en) 2017-08-03
JO3316B1 (ar) 2019-03-13
JP6387433B2 (ja) 2018-09-05
KR20160003110A (ko) 2016-01-08
UA118759C2 (uk) 2019-03-11
EP3004061B8 (en) 2017-10-04
ME02838B (me) 2018-01-20
PL3004061T3 (pl) 2018-01-31
CR20150622A (es) 2016-01-06
TN2015000514A1 (en) 2017-04-06
CN105228985A (zh) 2016-01-06
US8962654B2 (en) 2015-02-24
BR112015029090B1 (pt) 2023-05-09
SG11201509310QA (en) 2015-12-30
ZA201508213B (en) 2017-08-30
BR112015029090A8 (pt) 2020-03-17
SI3004061T1 (sl) 2017-10-30
CA2912849C (en) 2017-05-30
EA201592082A1 (ru) 2016-04-29
JP2017178945A (ja) 2017-10-05
NZ713809A (en) 2019-11-29
JP2016520127A (ja) 2016-07-11
MX2015016495A (es) 2016-03-01
EP3004061B1 (en) 2017-08-30
MY180751A (en) 2020-12-08
PE20152032A1 (es) 2016-01-28
JP6130590B2 (ja) 2017-05-17
PH12015502658B1 (en) 2016-03-07
DK3004061T3 (en) 2017-10-23
HRP20171696T1 (hr) 2017-12-29
TW201940469A (zh) 2019-10-16
AU2014274435B2 (en) 2016-07-14
TWI691488B (zh) 2020-04-21
RS56294B1 (sr) 2017-12-29
US20140357664A1 (en) 2014-12-04
CA2912849A1 (en) 2014-12-04
DOP2015000289A (es) 2015-12-31
AU2014274435A1 (en) 2015-11-19
PT3004061T (pt) 2017-10-19
AP2015008867A0 (en) 2015-11-30
KR101808933B1 (ko) 2017-12-13
TW201536745A (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
BR112015029090A2 (pt) compostos de 3,4-di-hidroisoquinolin-2(1h)-ila
CL2015001358A1 (es) Potenciadores del cftr deuterados
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112014026703A2 (pt) inibidores de dna-pk
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
BR112014017021A8 (pt) inibidores de irak e usos dos mesmos
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
BR112015002275A2 (pt) processos e intermediários para a preparação de inibidores da integrase
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов
BR112015010196A2 (pt) métodos de tratar doença do fígado
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
BR112014009217A2 (pt) antibacterianos à base de fenicol
AR096310A1 (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2014, OBSERVADAS AS CONDICOES LEGAIS